Pfizer Inc. has a rare 3-year tariff exemption and margin defense amid global price parity risks. Click here to read an ...
Pfizer's coronavirus-related sales have fallen sharply -- and they may decline even further next year. The company is developing some promising products, including a flu vaccine and a weight loss ...
Pfizer Inc. (NYSE: PFE) is scheduled to provide its full-year 2026 financial guidance on Tuesday, with Bank of America Securities expecting the company's growth profile to closely resemble conditions ...
Yesterday, the Pharma giant Pfizer Inc. (PFE) took the unusual step of not only providing its full-year 2025 revenue and earnings numbers but also providing precise guidance for full-year 2026.
Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted ...
The Daily Overview on MSN
How safe is Pfizer's dividend as 2026 begins?
Pfizer heads into 2026 with a share price still shaped by the boom and bust of COVID products and a shareholder base that increasingly cares more about income than growth. The company's dividend has ...
Financial guidance for Adjusted(1) diluted EPS is calculated using approximately 5.71 billion weighted-average shares outstanding in 2025 and approximately 5.74 billion weighted-average shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results